Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Dabrafenib Plus Trametinib in Previously Treated BRAF(V600E)-Mutant Metastatic NSCLC
- ESR1 Mutation Analysis to Guide the Treatment of ER-Positive Advanced Breast Cancer
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer
- Lifestyle Factors Associated With Carcinoma Incidence and Mortality
- ASCO 2016: Dr. Lee Schwartzberg's Abstract Recommendations—ER-Positive Breast Cancer
- ASCO 2016: Dr. Lee Schwartzberg's Abstract Recommendations—HER2-Positive Breast Cancer
- ASCO 2016: Dr. Lee Schwartzberg's Abstract Recommendations—Triple-Negative Breast Cancer/Local Therapy
- Adjuvant Tamoxifen Provides a Survival Benefit Over No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer
- Neoadjuvant Pertuzumab and Trastuzumab in Locally Advanced, Inflammatory, or Early-Stage HER2+ Breast Cancer